Ibrutinib-induced severe liver injury

Amara G Nandikolla; Olga Derman; Deborah Nautsch; Qiang Liu; Hatef Massoumi; Sangeetha Venugopal; Ira Braunschweig; Murali Janakiram

doi:10.1002/ccr3.881

Ibrutinib-induced severe liver injury

Amara G Nandikolla, Olga Derman, Deborah Nautsch, Qiang Liu, Hatef Massoumi, Sangeetha Venugopal, Ira Braunschweig, Murali Janakiram

Research output: Contribution to journal › Article › peer-review

Abstract

Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As these drugs are novel, long-term or rare adverse events are not yet known. We report the first case of ibrutinib-induced severe liver injury in a patient with relapsed/refractory CLL.

Original language	English (US)
Pages (from-to)	735-738
Number of pages	4
Journal	Clinical Case Reports
Volume	5
Issue number	6
DOIs	https://doi.org/10.1002/ccr3.881
State	Published - Jun 2017
Externally published	Yes

PubMed: MeSH publication types

Case Reports

Access

10.1002/ccr3.881

OpenUrl availability

Full text

Cite this

@article{87cba588e11d4267ac33e42b3b29f736,

title = "Ibrutinib-induced severe liver injury",

abstract = "Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As these drugs are novel, long-term or rare adverse events are not yet known. We report the first case of ibrutinib-induced severe liver injury in a patient with relapsed/refractory CLL.",

author = "Nandikolla, {Amara G} and Olga Derman and Deborah Nautsch and Qiang Liu and Hatef Massoumi and Sangeetha Venugopal and Ira Braunschweig and Murali Janakiram",

year = "2017",

month = jun,

doi = "10.1002/ccr3.881",

language = "English (US)",

volume = "5",

pages = "735--738",

journal = "Clinical Case Reports",

issn = "2050-0904",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Ibrutinib-induced severe liver injury

AU - Nandikolla, Amara G

AU - Derman, Olga

AU - Nautsch, Deborah

AU - Liu, Qiang

AU - Massoumi, Hatef

AU - Venugopal, Sangeetha

AU - Braunschweig, Ira

AU - Janakiram, Murali

PY - 2017/6

Y1 - 2017/6

N2 - Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As these drugs are novel, long-term or rare adverse events are not yet known. We report the first case of ibrutinib-induced severe liver injury in a patient with relapsed/refractory CLL.

AB - Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B-cell receptor pathway, is an effective therapeutic agent for B-cell lymphomas. As these drugs are novel, long-term or rare adverse events are not yet known. We report the first case of ibrutinib-induced severe liver injury in a patient with relapsed/refractory CLL.

U2 - 10.1002/ccr3.881

DO - 10.1002/ccr3.881

M3 - Article

C2 - 28588800

SN - 2050-0904

VL - 5

SP - 735

EP - 738

JO - Clinical Case Reports

JF - Clinical Case Reports

IS - 6

ER -

Ibrutinib-induced severe liver injury

Abstract

PubMed: MeSH publication types

Access

OpenUrl availability

Fingerprint

Cite this